Novartis stock sets 5% sales growth target through 2031
Published on 11/20/2026 at 11:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNovartis sets a longer-term growth path
- Management expects core operating margin to return above 40% by 2029.
- Peak sales targets rose for Kesimpta, Scemblix and Leqvio.
- The pipeline includes more than 35 potentially submission-enabling readouts through 2031.
On November 19, Novartis said in an ad hoc announcement that it expects net sales to grow at a 5% compound annual rate at constant currencies from 2026 through 2031. The Swiss drugmaker also said its core operating income margin is on track to return to above 40% by 2029.
Higher targets for key medicines
Novartis raised its peak sales outlook for three marketed medicines. Kesimpta, used in multiple sclerosis, now has a peak sales target of USD 8 billion, up from USD 6 billion. The company lifted its forecasts for leukemia treatment Scemblix and cholesterol medicine Leqvio to USD 5 billion each from USD 4 billion.
The changes build on a previous increase for Rhapsido, also known as remibrutinib, whose peak sales potential was raised to USD 8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis. Novartis said nine in-market assets now have peak sales potential between USD 3 billion and USD 10 billion.
Pipeline carries the longer-term case
The company said more than 35 potentially submission-enabling readouts are expected through 2031. Its pipeline contains more than 30 potential high-value assets across cardiovascular-renal-metabolic medicine, immunology, neuroscience and oncology. More than 20 are in registration, Phase II or Phase III, while more than 10 are in or entering Phase I.
Novartis presented the outlook at its Meet Novartis Management event in London. Chief Executive Vas Narasimhan said the upgraded brand forecasts, together with the broader portfolio, support the expectation of sustained mid-single-digit sales growth over the longer term. The company also highlighted efforts to scale artificial intelligence across research, development, manufacturing and commercial operations.
What the outlook means for investors
The announcement gives investors a clearer view of how Novartis intends to offset major loss-of-exclusivity effects while its newer medicines expand. The stronger forecasts for Kesimpta, Scemblix and Leqvio improve the contribution expected from products already on the market, but the longer-term plan still depends on successful clinical development, regulatory submissions and launches.
Novartis stock traded at 138.36 euros on Lang & Schwarz at 11:39 CET on Friday, November 20, 2026.
Novartis stock
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Exchange: Lang & Schwarz
- Price: 138.36 euros on November 20, 2026 at 11:39 CET
Swiss equities are tracked through the SMI.
